In this study, we have determined the effect of tinostamustine in increasing the expression of both CD38, the target of daratumumab, and ligands for NK cell-activating receptors on myeloma cells, and its effect in enhancing daratumumab’s efficacy in different preclinical models. This evidence concerns the gene CD38 and plasma cell myeloma.